Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login and start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

68 results

Aetiology, Epidemiology, Screening and Prevention;  Genitourinary Cancers

Urachal Cancer Prognosis Better Than Expected

From ESMO Congress 2022:
A study of patients with urachal cancer suggests that the median overall survival duration from this rare tumour type may be longer than previously reported

Anticancer Agents;  Prostate Cancer

STAMPEDE: No Additional mHSPC Benefit With Enzalutamide

From ESMO Congress 2022:
Use of enzalutamide alongside abiraterone plus steroids and androgen deprivation therapy does not further improve overall survival of metastatic hormone-sensitive prostate cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.